A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK112 in Patients With Non-Small Cell Lung Cancer

This is an early-phase study testing the safety, tolerability, and appropriate dosing of ABSK112, an experimental oral drug, in people with advanced non-small cell lung cancer (NSCLC). A specific group of interest is patients whose cancer has a type of EGFR mutation called an exon 20 insertion. **You may be eligible if...** - You are 18 years old or older - You have locally advanced or metastatic non-small cell lung cancer confirmed by biopsy - Your cancer has progressed after standard treatment, or you have no other treatment options - In the expansion phase: your tumor has a documented EGFR exon 20 insertion mutation - Your cancer is measurable on imaging - Your overall health status is acceptable (ECOG 0–1) - Your blood pressure is adequately controlled **You may NOT be eligible if...** - You have a specific EGFR mutation called C797S - You have had another primary cancer (with some exceptions) - You are pregnant or breastfeeding - You are unable to use effective contraception Talk to your doctor to see if this trial is right for you.